LENZ Therapeutics, Inc. — Director's Dealing 2021

Jun 25, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Graphite Bio, Inc. (GRPH)
CIK: 0001815776
Period of Report: 2021-06-24

Reporting Person: Hege Kristen (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$7.23	2031-04-14	Common Stock (93585)		Direct

Footnotes

F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on the last day of each calendar month after April 12, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.